Objectives: Psoriasis is a chronic inflammatory disease that is associated with a prothrombotic state and cardiovascular disease, including atrial fibrillation and thromboembolism. We therefore evaluated the impact of psoriasis in patients with atrial fibrillation and the performance of the CHA2 DS2 VASc score in these patients VSports手机版. .

Design, setting and participants: The study comprised all Danish patients hospitalized with nonvalvular atrial fibrillation in the period 1997-2011 (n = 99,357) V体育安卓版. Follow-up started 7 days from discharge and excluded subjects treated with anticoagulation. Poisson regression adjusted for CHA2 DS2 VASc score was used to estimate the incidence rate ratios and 95% confidence intervals. .

Main outcome measure: Hospitalization or death from thromboembolism V体育ios版. .

Results: Mean follow-up was 3. 5, 3. 1, and 2. 8 years for patients with no psoriasis, mild psoriasis and severe psoriasis, respectively. Patients with psoriasis were younger compared to patients without psoriasis, but CHA2DS2VASc score did not differ between the three groups. Thromboembolism rates per 100 patient-years (95% confidence intervals) were 4. 8 (4. 7-4. 9), 4. 8 (4. 2-5. 4) and 6. 1 (5. 0-7. 5) for patients with no psoriasis, mild psoriasis and severe psoriasis, respectively. Importantly, the observed thromboembolism rates in patients with severe psoriasis were markedly higher (2. 6- to3. 4-fold) than predicted by the CHA2 DS2 VASc score. Relative to no psoriasis, incidence rate ratios were 0 VSports最新版本. 99 (0. 87-1. 11) and 1. 27 (1. 02-1. 57) for mild and severe psoriasis, respectively. Correspondingly, incidence rate ratios for fatal stroke were 0. 97 (0. 80-1. 12) and 1. 51 (1. 12-2. 05). .

Conclusions: In patients with nonvalvular atrial fibrillation not treated with oral anticoagulation, severe psoriasis was associated with increased risk of thromboembolism V体育平台登录. In these patients, CHA2 DS2 VASc underestimated the risk of thromboembolism. .